company background image
BIIB logo

Biogen NasdaqGS:BIIB Stock Report

Last Price

US$160.85

Market Cap

US$23.9b

7D

2.0%

1Y

-29.9%

Updated

03 Dec, 2024

Data

Company Financials +

BIIB Stock Overview

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. More details

BIIB fundamental analysis
Snowflake Score
Valuation5/6
Future Growth1/6
Past Performance3/6
Financial Health6/6
Dividends0/6

Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

Biogen Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Biogen
Historical stock prices
Current Share PriceUS$160.85
52 Week HighUS$268.30
52 Week LowUS$153.62
Beta-0.081
11 Month Change-7.45%
3 Month Change-21.52%
1 Year Change-29.93%
33 Year Change-29.09%
5 Year Change-45.88%
Change since IPO5,116.76%

Recent News & Updates

Biogen Q3 Earnings Review: Why I Remain Optimistic Despite Difficult Quarter

Oct 31

Recent updates

Biogen Q3 Earnings Review: Why I Remain Optimistic Despite Difficult Quarter

Oct 31

Does Biogen (NASDAQ:BIIB) Have A Healthy Balance Sheet?

Oct 01
Does Biogen (NASDAQ:BIIB) Have A Healthy Balance Sheet?

What You Can Learn From Biogen Inc.'s (NASDAQ:BIIB) P/E

Sep 04
What You Can Learn From Biogen Inc.'s (NASDAQ:BIIB) P/E

Biogen: Q2 Earnings, Share Price May Have Bottomed Out As CEO Makes Mark

Aug 17

Biogen Stock: Cheapish, But With Few Growth Prospects

Jul 11

Is Biogen (NASDAQ:BIIB) Using Too Much Debt?

May 23
Is Biogen (NASDAQ:BIIB) Using Too Much Debt?

Biogen's Revenue Dip Meets Cost Cuts In Q1 (Rating Upgrade)

Apr 29

Earnings Update: Biogen Inc. (NASDAQ:BIIB) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

Apr 28
Earnings Update: Biogen Inc. (NASDAQ:BIIB) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

The Price Is Right For Biogen Inc. (NASDAQ:BIIB)

Apr 15
The Price Is Right For Biogen Inc. (NASDAQ:BIIB)

We Think You Can Look Beyond Biogen's (NASDAQ:BIIB) Lackluster Earnings

Feb 21
We Think You Can Look Beyond Biogen's (NASDAQ:BIIB) Lackluster Earnings

Biogen Inc. Just Missed EPS By 21%: Here's What Analysts Think Will Happen Next

Feb 16
Biogen Inc. Just Missed EPS By 21%: Here's What Analysts Think Will Happen Next

Biogen's Q4 Earnings Disappoint Amidst Strategic Challenges (Rating Downgrade)

Feb 14

Here's Why Biogen (NASDAQ:BIIB) Can Manage Its Debt Responsibly

Jan 31
Here's Why Biogen (NASDAQ:BIIB) Can Manage Its Debt Responsibly

Biotech And Pharma Diversification Pays Off

Jan 25

Getting In Cheap On Biogen Inc. (NASDAQ:BIIB) Might Be Difficult

Dec 26
Getting In Cheap On Biogen Inc. (NASDAQ:BIIB) Might Be Difficult

An Intrinsic Calculation For Biogen Inc. (NASDAQ:BIIB) Suggests It's 49% Undervalued

Oct 21
An Intrinsic Calculation For Biogen Inc. (NASDAQ:BIIB) Suggests It's 49% Undervalued

Is Biogen (NASDAQ:BIIB) Using Too Much Debt?

Oct 03
Is Biogen (NASDAQ:BIIB) Using Too Much Debt?

Is Biogen Inc. (NASDAQ:BIIB) Trading At A 31% Discount?

Jul 16
Is Biogen Inc. (NASDAQ:BIIB) Trading At A 31% Discount?

Shareholder Returns

BIIBUS BiotechsUS Market
7D2.0%-0.8%0.4%
1Y-29.9%12.9%32.3%

Return vs Industry: BIIB underperformed the US Biotechs industry which returned 12.9% over the past year.

Return vs Market: BIIB underperformed the US Market which returned 32.3% over the past year.

Price Volatility

Is BIIB's price volatile compared to industry and market?
BIIB volatility
BIIB Average Weekly Movement3.1%
Biotechs Industry Average Movement10.0%
Market Average Movement6.3%
10% most volatile stocks in US Market16.3%
10% least volatile stocks in US Market3.1%

Stable Share Price: BIIB has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: BIIB's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19787,570Chris Viehbacherwww.biogen.com

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies.

Biogen Inc. Fundamentals Summary

How do Biogen's earnings and revenue compare to its market cap?
BIIB fundamental statistics
Market capUS$23.93b
Earnings (TTM)US$1.62b
Revenue (TTM)US$9.61b

14.5x

P/E Ratio

2.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BIIB income statement (TTM)
RevenueUS$9.61b
Cost of RevenueUS$2.35b
Gross ProfitUS$7.26b
Other ExpensesUS$5.65b
EarningsUS$1.62b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)11.08
Gross Margin75.59%
Net Profit Margin16.81%
Debt/Equity Ratio38.5%

How did BIIB perform over the long term?

See historical performance and comparison